CardioDX, a cardiovascular genomic diagnostics company, plans to sell 5 million shares priced for between $14 and $16 apiece in its upcoming IPO. The midrange of the proposed offering would raise $75 million. CardioDX secured over $197 million in total VC funding and reached a valuation of $215 million in 2012 when it secured a $58 million round of financing led by Temasek Holdings (19.9% pre-IPO stake). Other investors in the company include Longitude Capital (17.9%), Artiman Ventures (13.9%) and Kleiner Perkins Caufield & Byers (9.5%), among others. CardioDX plans to list on the NASDAQ under the symbol CDX.